A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Clinical trial NCT03522246 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03522246
Sponsor: pharmaand GmbH
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Epithelial Ovarian Cancer Primary Peritoneal Fallopian Tube Cancer Newly Diagnosed FIGO Stage III-IV Partial Response Complete Response

Start date: 2018-05-14
Primary completion: 2024-05-20
Enrollment: 1097

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.